IPO News | French biotech company Theravectys plans to go public in Hong Kong or raise hundreds of millions of dollars

Zhitongcaijing · 3d ago

The Zhitong Finance App learned that according to media reports, French biotech company TheRavectys SA is considering an IPO in Hong Kong. According to people familiar with the matter, Theravectys is working with consultants to evaluate or raise hundreds of millions of dollars in IPO plans to be carried out as soon as this year. TheRavectys representatives have yet to respond.

TheRavectys is an immunotherapy company that mainly operates in France and the US. It was spun off by the Pasteur Institute (Pasteur Institute) to develop lentiviral vectors (lentiviral vectors) for the prevention and treatment of cancer and other diseases. Its supporters include Tethys Invest SAS.

Foreign biotech companies usually choose to go public in Europe or the US. For non-Chinese biotech companies, going public in Hong Kong is still rare. However, China is challenging Western dominance in medical innovation and reshaping the biotech industry. According to the data, health insurance companies raised a total of about 13 billion US dollars in the Hong Kong stock market last year.